Long-Term Clinical Benefits of a Platelet Glycoprotein IIb/IIIa Receptor Blocker, Abciximab (ReoPro (R) ), in High-Risk Diabetic Patients undergoing Percutaneous Coronary Intervention.
- Author:
Doo Sun SIM
1
;
Myung Ho JEONG
;
Weon KIM
;
Jay Young RHEW
;
Ju Hyup YUM
;
Ju Han KIM
;
Jeong Gwan CHO
;
Young Keun AHN
;
Jong Chun PARK
;
Byoung Hee AHN
;
Sang Hyung KIM
;
Jung Chaee KANG
Author Information
1. The Heart Center, Chonnam National University Hospital, Chonnam National University Research Institute of Medical Sciences, Gwangju, Korea. myungho@chollian.net
- Publication Type:Original Article ; Clinical Trial ; Comparative Study
- Keywords:
Platelets;
Diabetes;
Myocardial infarction;
Catheter-based coronary interventions
- MeSH:
*Angioplasty, Transluminal, Percutaneous Coronary;
Antibodies, Monoclonal/*therapeutic use;
Comparative Study;
Coronary Angiography;
Coronary Stenosis/*therapy;
Diabetes Mellitus/*complications/drug therapy/radiography;
Female;
Human;
Immunoglobulins, Fab/*therapeutic use;
Male;
Middle Aged;
Platelet Aggregation Inhibitors/*therapeutic use;
Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors;
Risk Factors;
Safety;
Stents;
Treatment Outcome
- From:The Korean Journal of Internal Medicine
2003;18(3):129-137
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: High-risk percutaneous coronary interventions (PCIs) are associated with a high complication rate, a low procedural success rate and a high restenosis rate, especially in diabetics. We sought to determine whether abciximab (ReoPro (R) ) therapy affects long-term clinical outcomes of Korean patients with diabetes undergoing high-risk PCI. METHODS: One hundred and nineteen patients with 152 lesion sites were administered ReoPro (R) among 2, 231 patients who underwent PCI at Chonnam National University Hospital from March 1999 to Feb 2001. These 119 patients were divided into two groups, 30 were allocated to a diabetic group (Group I, 57.7 +/- 8.2 years, 22 male), and 89 to a non-diabetic group (Group II, 59.6 +/- 10.8 years, 68 male). Early and long-term clinical outcomes after PCI were analyzed. RESULTS: In terms of clinical diagnosis, the number of acute myocardial infarctions in Group I was 25 (83.3%) and 76 in Group II (85.4%). As for risk factors, target artery lesions, and ACC/AHA types, no differences were found between the two groups. The number of patients with total occlusion was 21 (55.3%) and 62 (53.9%), and the number with a thrombus-containing lesion was 28 (93.3%) and 88 (98.9%) in Groups I and II, respectively. The procedure was successful in 27 (90.0%) in Group I, and in 80 (89.9%) in Group II, and no differences were evident between the two groups in terms of bleeding complications. No major adverse cardiac events (MACE), including myocardial infarction, repeat revascularization or cardiac death, were observed in Group I, but 8 cases of MACE occurred in Group II during hospitalization. Clinical follow-up was performed in 116 patients (97.5%) over 18.5 +/- 6.7 (5-28) months. The number of overall MACEs was 10 (3.3%) in Group I and 14 (15.7%) in Group II (p=0.038). CONCLUSION: ReoPro (R) used in high-risk PCI in diabetics was effective in terms of early clinical outcomes, but its long-term clinical benefits were not proven.
